Abbott starts pivotal trial of Cephea mitral valve replacement device

• Abbott initiated the CROWN-MV pivotal trial to evaluate its investigational Cephea mitral valve replacement system for patients ineligible for surgery or transcatheter repair.
• The study will enroll up to 585 patients across the U.S., Canada and Europe with significant mitral regurgitation or calcification-related valve dysfunction.
• Cephea delivers a tissue replacement valve through a leg vein, offering a potential minimally invasive treatment for patients with limited options.
• Early feasibility results will be presented at TCT on Nov. 1, 2026, addressing reduced valve leakage and improved quality of life.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abbott Laboratories published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610290900PR_NEWS_USPR_____CG81405) on October 29, 2026, and is solely responsible for the information contained therein.